
|Videos|October 11, 2016
Promising Alzheimer Antibody-Based Immunotherapy
Author(s)Bobby Lazzara, MD
Dr. Bobby Lazzara reports on a clinical trial of aducanumab, a human monoclonal antibody, in patients with prodromal or mild Alzheimer disease.
Advertisement
Aducanumab, a human monoclonal antibody, selectively targets aggregated amyloid-β. In this Medical News Minute, developed exclusively for Neurology Times, Dr. Bobby Lazzara discusses a
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
2
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
3
FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date
4
Building the Foundation for Earlier Alzheimer Disease Diagnosis
5


















